Cancer Research · 2017 · 94 citations · 34 references
MedicineOncologyPharmacologyCellular MetabolismChemotherapyMolecular OncologyAlkylating AgentsCancer MetabolismEnzyme InhibitionMetabolic ReprogrammingMetabolic Reprogramming In CancerMolecular Mechanisms Of ToxicityAlkylating Agent CombinationsAnticancer ActivityAnticancer ChemotherapyDrug-induced Dna DamageNad+ Metabolism In Dna RepairNad-dependent EnzymesNicotinamide PhosphoribosyltransferaseTemozolomide Therapy
Abstract IDH1-mutant gliomas are dependent upon the canonical coenzyme NAD+ for survival. It is known that PARP activation consumes NAD+ during base excision repair (BER) of chemotherapy-induced DNA damage. We therefore hypothesized that a strategy combining NAD+ biosynthesis inhibitors with the alkylating chemotherapeutic agent temozolomide could potentiate NAD+ depletion–mediated cytotoxicity in mutant IDH1 cancer cells. To investigate the impact of temozolomide on NAD+ metabolism, patient-derived xenografts and engineered mutant IDH1-expressing cell lines were exposed to temozolomide, in vitro and in vivo, both alone and in combination with nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, which block NAD+ biosynthesis. The acute time period (<3 hours) after temozolomide treatment displayed a burst of NAD+ consumption driven by PARP activation. In IDH1-mutant–expressing cells, this consumption reduced further the abnormally lowered basal steady-state levels of NAD+, introducing a window of hypervulnerability to NAD+ biosynthesis inhibitors. This effect was selective for IDH1-mutant cells and independent of methylguanine methyltransferase or mismatch repair status, which are known rate-limiting mediators of adjuvant temozolomide genotoxic sensitivity. Combined temozolomide and NAMPT inhibition in an in vivo IDH1-mutant cancer model exhibited enhanced efficacy compared with each agent alone. Thus, we find IDH1-mutant cancers have distinct metabolic stress responses to chemotherapy-induced DNA damage and that combination regimens targeting nonredundant NAD+ pathways yield potent anticancer efficacy in vivo. Such targeting of convergent metabolic pathways in genetically selected cancers could minimize treatment toxicity and improve durability of response to therapy. Cancer Res; 77(15); 4102–15. ©2017 AACR.
34
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin et al. · New England Journal of Medicine · 2009 · 5.9K citations · Full text
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons, Siân Jones, Xiaosong Zhang et al. · Science · 2008 · 5.8K citations · Full text
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang, David W. White, Bryson D. Bennett et al. · Nature · 2009 · 4.1K citations · Full text